Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents

摘要: Poor-risk metastatic renal cell carcinoma (RCC) includes a subgroup of patients with unfavorable prognosis, according to both the Motzer and Heng criteria. Overall, owing poor prognosis these patients, approach is still challenge for first subsequent lines treatment, particularly rare histologies other than clear carcinoma. In this review, we investigated present treatment option poor-risk RCC. Areas covered are data further line therapy mTOR inhibitors agents but without cytoreductive nephrectomy or histologies. The current on systemic in RCC maintain temsirolimus as preferred first-line therapy. New targeting immune checkpoints being developed clinical trials.